Advertorial

Expert view: Advancing antibody discovery with picodroplet technology

Posted: 13 September 2019 | | No comments yet

It is predicted that there will be 70 new monoclonal antibody (mAb) biotherapeutics available by 2020.

This increased focus on biologics discovery increases the pressure to reduce discovery and development timelines, resulting in the need for more efficient screening and more precise methods for mAb production.1

Current methods used in antibody discovery such as hybridomas, humanisation of rodent antibodies and display technologies are well established with proven success rates – more than 60 mAbs have been approved by the US Food and Drug Administration (FDA).1,2,3 However, the semi-automated technologies currently used are not efficient enough to meet the growing demand for new therapeutics, being time-consuming, resource-intensive with a low screening throughput of antibody-secreting cells. Therefore, there is an urgent need for novel technologies to enable the high-throughput screening, detection and isolation of those rare cells secreting antigen-specific antibodies.











To read this Expert View in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: Sphere Fluidics

Send this to a friend